Who is sponsoring NCT01765218?

NCT01765218 is sponsored by Kristin R Hoffman.

What condition does NCT01765218 study?

NCT01765218 studies Hypoxic Ischemic Encephalopathy.

What drugs are being tested in NCT01765218?

Interventions: Topiramate, Placebo.

What is the status of NCT01765218?

NCT01765218 is currently TERMINATED.

Last reviewed 2024-05-15 · How we verify

Topiramate as an Adjuvant to Therapeutic Hypothermia for Infants With Hypoxic Ischemic Encephalopathy

NCT01765218 Phase 1/Phase 2 TERMINATED Results posted

The goal is to see whether topiramate (an anti-epileptic agent) improves the outcome of babies with neonatal hypoxic encephalopathy who are receiving whole body cooling.

Details

Lead sponsor	Kristin R Hoffman
Phase	Phase 1/Phase 2
Status	TERMINATED
Enrolment	34
Start date	2013-02
Completion	2022-01-27

Conditions

Hypoxic Ischemic Encephalopathy

Interventions

Topiramate
Placebo

Primary outcomes

Number of Patients With Seizures — At 4 weeks post-natal age or the time of hospital discharge (whichever is earlier)
Clinical or electrical seizures occuring before hospital discharge or before 4w post-natal age (which ever is earlier) will be compared between the topiramate and control groups.

Countries

United States